These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15110788)

  • 1. The gene-silencing efficiency of siRNA is strongly dependent on the local structure of mRNA at the targeted region.
    Luo KQ; Chang DC
    Biochem Biophys Res Commun; 2004 May; 318(1):303-10. PubMed ID: 15110788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo.
    Gao L; Zhang L; Hu J; Li F; Shao Y; Zhao D; Kalvakolanu DV; Kopecko DJ; Zhao X; Xu DQ
    Clin Cancer Res; 2005 Sep; 11(17):6333-41. PubMed ID: 16144938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local RNA target structure influences siRNA efficacy: a systematic global analysis.
    Overhoff M; Alken M; Far RK; Lemaitre M; Lebleu B; Sczakiel G; Robbins I
    J Mol Biol; 2005 May; 348(4):871-81. PubMed ID: 15843019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature.
    Anderson EM; Miller P; Ilsley D; Marshall W; Khvorova A; Stein CA; Benimetskaya L
    Cancer Gene Ther; 2006 Apr; 13(4):406-14. PubMed ID: 16195754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A structure-activity relationship study of siRNAs with structural variations.
    Chang CI; Hong SW; Kim S; Lee DK
    Biochem Biophys Res Commun; 2007 Aug; 359(4):997-1003. PubMed ID: 17577577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Choice of the adequate detection time for the accurate evaluation of the efficiency of siRNA-induced gene silencing.
    Choi I; Cho BR; Kim D; Miyagawa S; Kubo T; Kim JY; Park CG; Hwang WS; Lee JS; Ahn C
    J Biotechnol; 2005 Nov; 120(3):251-61. PubMed ID: 16095743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential design rules and enzymatic synthesis of siRNAs.
    Sioud M; Leirdal M
    Methods Mol Biol; 2004; 252():457-69. PubMed ID: 15017071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational models with thermodynamic and composition features improve siRNA design.
    Shabalina SA; Spiridonov AN; Ogurtsov AY
    BMC Bioinformatics; 2006 Feb; 7():65. PubMed ID: 16472402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.
    Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY
    Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual gene targeted multimeric siRNA for combinatorial gene silencing.
    Lee SH; Mok H; Jo S; Hong CA; Park TG
    Biomaterials; 2011 Mar; 32(9):2359-68. PubMed ID: 21183215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene silencing activity of siRNAs with a ribo-difluorotoluyl nucleotide.
    Xia J; Noronha A; Toudjarska I; Li F; Akinc A; Braich R; Frank-Kamenetsky M; Rajeev KG; Egli M; Manoharan M
    ACS Chem Biol; 2006 Apr; 1(3):176-83. PubMed ID: 17163665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local RNA target structure influences siRNA efficacy: systematic analysis of intentionally designed binding regions.
    Schubert S; Grünweller A; Erdmann VA; Kurreck J
    J Mol Biol; 2005 May; 348(4):883-93. PubMed ID: 15843020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.
    Benimetskaya L; Ayyanar K; Kornblum N; Castanotto D; Rossi J; Wu S; Lai J; Brown BD; Popova N; Miller P; McMicken H; Chen Y; Stein CA
    Clin Cancer Res; 2006 Aug; 12(16):4940-8. PubMed ID: 16914583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SiRNAs do not induce RNA-dependent transcriptional silencing of retrovirus in human cells.
    Haraguchi T; Mizutani T; Yamamichi N; Ito T; Minoguchi S; Iba H
    FEBS Lett; 2007 Oct; 581(25):4949-54. PubMed ID: 17904125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Competition potency of siRNA is specified by the 5'-half sequence of the guide strand.
    Yoo JW; Kim S; Lee DK
    Biochem Biophys Res Commun; 2008 Feb; 367(1):78-83. PubMed ID: 18164261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules.
    Opalinska JB; Kalota A; Gifford LK; Lu P; Jen KY; Pradeepkumar PI; Barman J; Kim TK; Swider CR; Chattopadhyaya J; Gewirtz AM
    Nucleic Acids Res; 2004; 32(19):5791-9. PubMed ID: 15514112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of target site accessibility on the design of effective siRNAs.
    Tafer H; Ameres SL; Obernosterer G; Gebeshuber CA; Schroeder R; Martinez J; Hofacker IL
    Nat Biotechnol; 2008 May; 26(5):578-83. PubMed ID: 18438400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico selection of active siRNA.
    Patzel V
    Drug Discov Today; 2007 Feb; 12(3-4):139-48. PubMed ID: 17275734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of human immunodeficiency virus type 1 replication by siRNA targeted to the highly conserved primer binding site.
    Han W; Wind-Rotolo M; Kirkman RL; Morrow CD
    Virology; 2004 Dec; 330(1):221-32. PubMed ID: 15527848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An siRNA-based system for differential regulation of ectopic gene expression constructs.
    Hahn P; Niemann G; Grewe A; Bielke W
    J Biotechnol; 2007 Mar; 128(4):762-9. PubMed ID: 17258833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.